BURNETT JOSEPH 4

What Happened

• Joseph Burnett, CEO, President and a director of ClearPoint Neuro, was granted 147,275 restricted stock units (RSUs) on February 17, 2026. The award is recorded as a derivative acquisition with an acquisition price of $0.00 on the Form 4 (transaction code A — award/grant). Each RSU represents a contingent right to receive one share of CLPT common stock upon vesting.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-19 (appears filed within the required reporting window).
• Grant: 147,275 RSUs; acquisition price reported as $0.00 (derivative award).
• Vesting (per filing footnotes): 20% on Feb 17, 2027; 40% on Feb 17, 2028; 40% on Feb 17, 2029.
• Shares owned after the transaction: Not specified in the provided Form 4 excerpt.
• Transaction type/code: A (award/grant); derivative (RSUs); no 10b5-1, tax-withholding, or late-filing flags noted in the provided data.

Context

• RSU grants are typical executive compensation and are subject to the vesting schedule above; they do not represent immediately saleable shares until vested (and any withholding or release conditions are met). This is a compensation award rather than an open-market purchase or sale and should be interpreted as part of Burnett’s pay package, not a direct market sentiment signal.